mRNA and Delivery / Lipids and LNP Excipients
SM-102
Quick view. SM-102 (CAS 2089251-47-6) is listed for identity-scoped inquiry through OROGO. Current availability, exact chemical form, specification and packaging are confirmed for each request; this listing makes no stock or suitability claim. Catalog target purity: Specification by inquiry. Availability: Inquiry only — contact OROGO to confirm current availability.
Request a quote Review request checklist
Catalog status
Scope. "Available for inquiry" is not a stock claim. Operating tier is a catalog-merchandising priority. Development phase and program context are shown only where the reviewed catalog source provides a mapping; they describe the chemistry platform and do not claim that OROGO supplies the named program.
| Supply status | Available for inquiry |
|---|---|
| Operating tier | Core |
| Reviewed supporting program count | 1 |
| Representative chemistry-platform program | Spikevax |
| Highest development phase | Marketed |
| CAS status | Published registry number |
Product profile
SM-102 is classified as mrna and delivery / lipids and lnp excipients (Formula C44H87NO5; molecular weight 710.20).
SM-102 is supplied for research use within the Specialty Amphiphilic Compounds product family.
For SM-102, confirm the current specification, storage conditions and downstream-method compatibility before routine use.
Names and search terms
Useful catalog search terms
- 2089251-47-6
Physicochemical data
| Reviewed identity | SM-102 |
|---|---|
| PubChem CID | 126697616 |
| InChI | InChI=1S/C44H87NO5/c1-4-7-10-13-16-17-18-24-32-41-49-43(47)35-29-25-31-38-45(39-40-46)37-30-23-19-22-28-36-44(48)50-42(33-26-20-14-11-8-5-2)34-27-21-15-12-9-6-3/h42,46H,4-41H2,1-3H3 |
| InChIKey | BGNVBNJYBVCBJH-UHFFFAOYSA-N |
| SMILES | CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO |
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.